UroGen begins subject dosing in Phase III bladder cancer drug trial
The single-arm, multicentre trial will assess the efficacy and safety of the potential treatment.
03 October 2024
03 October 2024
The single-arm, multicentre trial will assess the efficacy and safety of the potential treatment.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.